The fixed duration or time-limited treatment for chronic lymphocytic leukemia patients has been an attractive option. The time-limited treatment means that patients can be observed after completion of their treatment.
This has been studied with ibrutinib (IMBRUVICA) and Venetoclax (VENCLEXTA) drug combination. The clinical trial is Glow study published in New England Journal of Medicine in May 2022. Patient were treated for initial three months with BTK inhibitor drug called ibrutinib and followed by one year treatment with a combination of ibrutinib and venetoclax.
After a median follow-up of 27.7 months, the PFS was significantly longer for ibrutinib-venetoclax than for chlorambucil-obinutuzumab (hazard ratio, 0.216; 95% confidence interval [CI], 0.131 to 0.357; P<0.001). There was improvement in progression free survival with ibrutinib-venetoclax combination across most of the predefined subgroups. This is also an all Oral drug therapy or treatment regimen and does not need an intravenous infusions.
